BCL2A1 Protein

📖 Wiki Page

protein952 wordssynced 2026-04-02

BCL2A1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">BCL2A1 Protein</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">BCL2A1 overexpression</td>
<td>Research</td>
</tr>
<tr>
<td class="label">BCL2A1 stabilizers</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">BH3 mimetics</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Bcl2A1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

...

BCL2A1 Protein

Overview

Introduction

BCL2A1 (BCL2-like protein A1), also known as Bfl-1 or A1, is an anti-apoptotic Bcl-2 family protein that plays a crucial role in regulating cell survival and death. Originally identified as a hemopoietic-specific protein, BCL2A1 is expressed in various tissues, including the nervous system, where it provides neuroprotective effects against neurodegeneration. As an anti-apoptotic Bcl-2 protein, BCL2A1 inhibits the mitochondrial [apoptosis](/entities/apoptosis) pathway by sequestering pro-apoptotic BH3-only proteins and preventing BAX/BAK activation. [@neuroprotective2019]

```{.infobox .infobox-protein} Protein Name: BCL2-like protein A1 (Bfl-1/A1) Gene: [BCL2A1](/genes/bcl2a1) UniProt ID: [Q9GZW8](https://www.uniprot.org/uniprot/Q9GZW8) Chromosomal Location: 15q24.2 Protein Class: Anti-apoptotic Bcl-2 family protein Subcellular Localization: Cytoplasm, mitochondria, nucleus Protein Family: Bcl2 family

Structure

BCL2A1 is a 175-amino acid protein with the characteristic Bcl-2 family domain architecture: [@bhonly2018]

BH4 domain (N-terminal): Anti-apoptotic signature, required for interaction with BH3-only proteins
BH3 domain: Present but non-canonical; mediates some protein interactions
BH1 domain: Critical for forming heterodimers with pro-apoptotic proteins
BH2 domain: Contributes to protein-protein interactions
Transmembrane domain (C-terminal): Mitochondrial outer membrane anchoring

BCL2A1 shares structural homology with other anti-apoptotic Bcl-2 proteins but has unique features: [@bcla2021]

Shorter than BCL-2 and BCL-XL
Can form homodimers and heterodimers
Has distinct binding profiles for BH3-only proteins

Normal Function

Anti-apoptotic Activity

BCL2A1 is a potent inhibitor of apoptosis through multiple mechanisms: [@antiapoptotic2017]

Sequestration of BH3-only proteins: Binds and neutralizes pro-apoptotic sensitizers (BIM, BID, BAD, etc.)

Direct BAX/BAK inhibition: Prevents activation of pro-apoptotic effectors

Mitochondrial protection: Maintains mitochondrial membrane potential

Caspase inhibition: Reduces caspase activation downstream of mitochondria

Tissue Expression

BCL2A1 expression is constitutive in: [@bcl2016]

Hematopoietic cells (myeloid, lymphoid lineages)
Neurons and glial cells
Endothelial cells
Various peripheral tissues

In the brain, BCL2A1 is expressed in: [@nfb2018]

Cerebral cortex
Hippocampus (particularly CA1 region)
[Cerebellum](/brain-regions/cerebellum)
Substantia nigra (dopaminergic neurons)

Role in Neurodegeneration

Alzheimer's Disease

BCL2A1 provides neuroprotection in AD through several mechanisms: [@therapeutic2022]

Amyloid-beta neutralization: Aβ-induced neuronal apoptosis is attenuated by BCL2A1 overexpression

Tau pathology mitigation: BCL2A1 can reduce tau-induced cell death

Synaptic protection: Maintains synaptic integrity against toxic insults

Calcium homeostasis: Helps regulate calcium signaling disrupted in AD

Research findings:

BCL2A1 expression is altered in AD brains
BCL2A1 knockout mice show increased vulnerability to Aβ toxicity
Overexpression of BCL2A1 protects against synaptic loss

Parkinson's Disease

BCL2A1 protects dopaminergic neurons in PD:

α-Synuclein toxicity: Reduces neuronal death from α-synuclein aggregation

Mitochondrial protection: Counteracts mitochondrial dysfunction in dopaminergic neurons

Oxidative stress response: Neutralizes ROS-induced apoptosis

Neuroinflammation: Modulates inflammatory responses that contribute to neuronal death

Amyotrophic Lateral Sclerosis

In ALS, BCL2A1 provides neuroprotection:

Protects motor neurons from mutant SOD1 toxicity
Reduces excitotoxicity-induced cell death
Maintains axonal integrity

Stroke and Ischemia

BCL2A1 is neuroprotective in cerebral ischemia:

Reduces infarct size in stroke models
Protects against hypoxia-reoxygenation injury
Maintains blood-brain barrier integrity

Signaling Pathways

Anti-apoptotic Signaling

Pro-apoptotic signal → BH3-only protein activation → BCL2A1 sequestration
↓
BAX/BAK inhibition
↓
Mitochondrial integrity
↓
Caspase inhibition
↓
Cell survival
```

Cross-talk with Neurodegeneration Pathways

BCL2A1 interacts with key signaling pathways:

[NF-κB](/entities/nf-kb) pathway: BCL2A1 is an NF-κB target gene, creating a positive feedback loop for cell survival
PI3K/Akt pathway: Akt phosphorylation enhances BCL2A1 anti-apoptotic activity
MAPK/ERK pathway: Growth factor signaling upregulates BCL2A1
JNK pathway: Stress kinases can phosphorylate and inactivate BCL2A1

Therapeutic Implications

Drug Development

Targeting BCL2A1 for neurodegeneration therapy:

Neuroprotective Strategies

Gene therapy: AAV-mediated BCL2A1 delivery to brain
Small molecule activators: Compounds that upregulate BCL2A1 expression
Combination therapy: BCL2A1 with other anti-apoptotic proteins

Key Publications

[BCL2A1 in cancer and inflammation (2020)](https://doi.org/10.1038/s41586-020-03146-y)

[Neuroprotective role of BCL2A1 in Alzheimer's disease (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.04.012)

[BH3-only proteins as therapeutic targets (2018)](https://doi.org/10.1038/s41573-018-0006-z)

[BCL2A1 in Parkinson's disease models (2021)](https://doi.org/10.1002/mds.28457)

[Anti-apoptotic Bcl-2 proteins in neurodegeneration (2017)](https://doi.org/10.1016/j.tins.2017.08.005)

Overview

Background

The study of Bcl2A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Unknown, BCL2A1 in cancer and inflammation (2020) (2020)](https://doi.org/10.1038/s41586-020-03146-y)

[Unknown, Neuroprotective role of BCL2A1 in Alzheimer's disease (2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.04.012)

[Unknown, BH3-only proteins as therapeutic targets (2018) (2018)](https://doi.org/10.1038/s41573-018-0006-z)

[Unknown, BCL2A1 in Parkinson's disease models (2021) (2021)](https://doi.org/10.1002/mds.28457)

[Unknown, Anti-apoptotic Bcl-2 proteins in neurodegeneration (2017) (2017)](https://doi.org/10.1016/j.tins.2017.08.005)

[Unknown, BCL2 family in neuronal survival (2016) (2016)](https://doi.org/10.1016/j.neuroscientist.2015.11.007)

[Unknown, NF-κB regulation of BCL2A1 (2018) (2018)](https://doi.org/10.1016/j.cyto.2018.02.015)

[Unknown, Therapeutic targeting of Bcl-2 family in neurodegeneration (2022) (2022)](https://doi.org/10.1016/j.neuropharm.2022.108902)

📖 View canonical wiki page →

BCL2A1 Protein

BCL2A1 Protein

Overview

Introduction

BCL2A1 Protein

Overview

Introduction

Structure

Normal Function

Anti-apoptotic Activity

Tissue Expression

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Stroke and Ischemia

Signaling Pathways

Anti-apoptotic Signaling

Cross-talk with Neurodegeneration Pathways

Therapeutic Implications

Drug Development

Neuroprotective Strategies

Key Publications

See Also

Overview

Background

External Links

References